Autopsy report · NCT02044848
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
Cause of deathFunding or business
“This study was terminated prematurely by the Sponsor for business reasons only.”
Life of this trial
- Ran for about 7 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Secukinumab; Placebo
- Participants
- 5
- Sites
- 2
- Countries
- United States
Trials that died the same way
- A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
“The study was terminated early as per Sponsor's decision” - Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
“This study was terminated by the Sponsor.” - Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
“The study was terminated by the sponsor” - Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
“This study was terminated based on a business decision by the Sponsor.” - Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
“Study terminated by sponsor for commercial reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.